Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio Spearhead 1 en sujetos con sarcoma sinovial avanzado o liposarcoma mixoide/de células redondas

3 de noviembre de 2026 actualizado por: USWM CT, LLC

Ensayo clínico abierto de fase 2 de un solo brazo de células T ADP-A2M4 SPEAR™ en sujetos con sarcoma sinovial avanzado o liposarcoma mixoide/de células redondas

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

52

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M9
        • Princess Margaret Cancer Centre
      • Madrid, España, 28040
        • Start Madrid-FJD, Fundación Jimѐnez Díaz
      • Seville, España, 41013
        • Hospital Universitario Virgen del Rocio
    • Catalonia
      • Barcelona, Catalonia, España, 119-129
        • Hospital Universitari Vall D'Hebron
    • California
      • Duarte, California, Estados Unidos, 91010
        • City of Hope
      • Palo Alto, California, Estados Unidos, 94305
        • Stanford Cancer Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • University of Colorado
    • Florida
      • Jacksonville, Florida, Estados Unidos, 33612
        • Mayo Clinic Jacksonville
      • Tampa, Florida, Estados Unidos, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University Robert H. Lurie Comprehensive Cancer Center
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • National Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02215
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan-Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37212
        • Vanderbilt
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Fred Hutch
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of WI Froedtert Hospital
      • Lyon, Francia
        • Centre Leon Berard
      • Pessac, Francia, 33604
        • Hospital Haut Leveque, CHU Bordeaux
      • Villejuif, Francia, 94805
        • Gustave Roussy Cancer Center
      • London, Reino Unido, NW1 2PG
        • UCLH Cancer Clinical Trials Unit
      • Manchester, Reino Unido, M20 4BX
        • The Christie NHS Foundation Trust

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

10 años a 75 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria

  • Age ≥16 (10 years at selected sites) and <=75 years
  • Diagnosis of advanced synovial sarcoma (Cohort 1, Cohort 2 and Cohort 3) or myxoid liposarcoma / myxoid round cell liposarcoma (Cohort 1 only) confirmed by cytogenetics.
  • Previously received either an anthracycline or ifosfamide containing regimen.
  • Measurable disease according to RECIST v1.1 prior to lymphodepletion
  • HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 positive
  • Tumor shows MAGE-A4 expression confirmed by central laboratory. North America Only (United States and Canada): Tumor (either an archival specimen or a fresh biopsy) shows MAGE-A4 expression of ≥2+ staining in ≥30% of the cells by immunohistochemistry.
  • ECOG Performance Status of 0 or1. For subjects aged ≥10 to ≥16 years old:

Lansky Score ≥60%.

• Left ventricular ejection fraction (LVEF) ≥50%.

Note: other protocol defined Inclusion criteria may apply

Key Exclusion Criteria:

  • HLA-A*02:05 in either allele
  • Received or plans to receive the following therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy: Cytotoxic chemotherapy, Tyrosine kinase inhibitor (TKI) (e.g. pazopanib), Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors,), Anti-cancer Vaccine, Gene therapy using an integrating vector (subjects who have received a gene therapy using a lentiviral vector may be eligible for the study), Corticosteroids or any other immunosuppressive therapy, Investigational treatment or interventional clinical trial, Allogeneic hematopoietic stem cell transplant, Radiotherapy to the target lesions, Major surgery
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
  • History of autoimmune or immune mediated disease
  • Symptomatic CNS metastases including leptomeningeal disease.
  • Other prior malignancy that is not considered by the Investigator to be in complete remission
  • Clinically significant cardiovascular disease
  • Uncontrolled intercurrent illness
  • Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
  • Pregnant or breastfeeding

Note: other protocol defined Exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Células T autólogas genéticamente modificadas afamitresgene autoleucel (anteriormente ADP-A2M4) SPEAR™

Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate (ORR) (Cohort 1)
Periodo de tiempo: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

Percentage of participants with confirmed tumor response (complete [CR] or partial [PR] response) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Independent Radiologist review (Cohort 1)

From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adverse Events (AE) Including Serious Adverse Events (SAE), SAE, and Adverse Events of Special Interest (AESI) (Cohort 1)
Periodo de tiempo: AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).

An AE was defined as any untoward medical occurrence in a subject or clinical study participant temporally associated with the use of the study intervention, whether or not considered related to the study intervention. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants with AEs (including SAE), SAE and AESI including cytokine release syndrome, neurotoxicity, ICANS, prolonged cytopenia are presented.

AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
The Number of Participants With Replication Competent Lentivirus (RCL)
Periodo de tiempo: From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).

The presence of RCL was assessed by qPCR targeting a segment of the vesicular stomatitis virus glycoprotein (VSV G) coding sequence.

From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
Insertional Oncogenesis (IO)
Periodo de tiempo: From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)

Deoxyribonucleic acid (DNA) from participants peripheral blood mononuclear cell (PBMC) samples was subjected to lentiviral vector integration site analysis by next-generation sequencing, thus evaluating both the clonality status of the transduced cell population and the genomic localization of individual integration sites. The count of participants with integration sites representing more than 5% of all unique sites is presented.

From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
Best Overall Response (BOR) (Cohort 1)
Periodo de tiempo: From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

BOR is the best response recorded from the start of T-cell infusion until disease progression/recurrence as assessed by Independent Radiologist review. Response categories are confirmed CR, confirmed PR, stable disease and confirmed progressive disease (PD). Best overall response is a stable disease, if CR or PR are unconfirmed.

From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
Time to Response (TTR) (Cohort 1)
Periodo de tiempo: From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.

TTR was defined as the interval (weeks) from the date of T-cell infusion to the earliest date of the first documented confirmed CR or confirmed PR as assessed by Independent Radiologist review. TTR (in weeks) = [date of initial confirmed CR or PR - date of T-cell infusion + 1]/7.

From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
Duration of Response (DoR) (Cohort 1)
Periodo de tiempo: From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.

DoR (in months) is defined as ((date of PD (or censoring) - date of initial confirmed CR/PR + 1)/365.25)*12 as assessed by Independent Radiologist review.

Outcome Measure not yet reached as participants are ongoing in study

From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
Progression Free Survival (PFS) (Cohort 1)
Periodo de tiempo: From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD

PFS is defined as the time from T-cell infusion to the date of the first documentation of PD or death due to any cause, whichever occurs first, as assessed by Independent Radiologist review. PFS (in weeks) was calculated as (date of PD/death [or censored date] - first T-cell infusion date + 1)/7.

From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
Overall Survival (OS) (Cohort 1)
Periodo de tiempo: From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).

OS is defined as the time from the date of T-cell infusion to the date of death (due to any reason) or censored date. OS in months was calculated as ((death date - first T-cell infusion date + 1)/365.25)*12.

Outcome Measure not yet reached as participants are ongoing in study

From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
Peak Persistence (Cohort 1)
Periodo de tiempo: From T-cell infusion to 3.2 years (as of data cut off).

Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).

From T-cell infusion to 3.2 years (as of data cut off).
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Periodo de tiempo: 2.5 years

Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry

2.5 years
Quantitation of Genetically Engineered T-cells in PBMCs
Periodo de tiempo: 2.5 years

Quantitation of genetically engineered T-cells in PBMCs by flow cytometry

2.5 years
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
Periodo de tiempo: 2.5 years

Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR

2.5 years
In Vitro Diagnostic (IVD) Assay for Screening
Periodo de tiempo: 2.5 years

Development and validation of the MAGE-A4 antigen expression companion diagnostic assay

2.5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Dejka Araujo, MD, MD Anderson Cancer Center; Houston TX 77030

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

13 de agosto de 2019

Finalización primaria (Actual)

29 de agosto de 2021

Finalización del estudio (Estimado)

1 de abril de 2038

Fechas de registro del estudio

Enviado por primera vez

9 de julio de 2019

Primero enviado que cumplió con los criterios de control de calidad

1 de agosto de 2019

Publicado por primera vez (Actual)

5 de agosto de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ADP 0044-002

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .